PATIENT INFORMATION LEAFLET
Losartán/Hydrochlorothiazide Mabo 50mg/12.5mg film-coated tablets
Read this leaflet carefully before you start taking the medicine.
1.What Losartán/Hydrochlorothiazide Mabo is and what it is used for
2.What you need to know before you start taking Losartán/Hydrochlorothiazide Mabo
3.How to take Losartán/Hydrochlorothiazide Mabo
4.Possible side effects
5Storage of Losartán/Hydrochlorothiazide Mabo
6.Contents of the pack and additional information
Losartán/Hidroclorotiazida Mabois a combination of an angiotensin II receptor antagonist (losartán) and a diuretic (hidroclorotiazida). Angiotensin II is a substance produced in the body that binds to receptors present in blood vessels, causing them to constrict. This results in an increase in blood pressure. Losartán prevents the binding of angiotensin II to these receptors, causing blood vessels to relax, which in turn reduces blood pressure. Hidroclorotiazida causes the kidneys to eliminate a greater amount of water and salts. This also helps to reduce blood pressure.
Losartán/Hidroclorotiazida Mabois indicated for the treatment of essential hypertension (high blood pressure).
Do not takeLosartán/Hidroclorotiazida Mabo
Warnings and precautions
Inform your doctor if you are pregnant (or if you suspect that you may be). Losartán/Hidroclorotiazida Mabo is not recommended for use at the start of pregnancy, and it should not be taken if you are more than 3 months pregnant as it may cause serious harm to your baby when administered from that time onwards (see Pregnancy section).
It is essential that you inform your doctor before taking Losartán/Hidroclorotiazida Mabo:
Your doctor may monitor your renal function, blood pressure, and electrolyte levels in the blood (e.g. potassium) at regular intervals. See also the information under the heading “Do not takeLosartán/Hidroclorotiazida Mabo”.
Other medicines and Losartán/Hidroclorotiazida Mabo
Inform your doctor or pharmacist if you are taking or have recently taken other medicines, including those purchased without a prescription.
Diuretics such as hydrochlorothiazide inLosartán/Hidroclorotiazida Mabomay interact with other medicines.
Preparations containing lithium should not be taken withLosartán/Hidroclorotiazida Mabowithout your doctor closely monitoring you.
Special precautions may be necessary (e.g. blood tests) if you take potassium supplements, salt substitutes containing potassium or potassium-sparing medicines, diuretics (urine-producing tablets), some laxatives, medicines for gout treatment, heart rhythm-controlling medicines or diabetes medicines (oral or insulin).
It is also essential that your doctor knows if you are taking:
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not takeLosartán/Hidroclorotiazida Mabo” and “Be careful withLosartán/Hidroclorotiazida Mabo”).
Please inform your doctor when you plan to have a contrast medium with iodine.
Consult your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking Losartán/Hidroclorotiazida Mabo. Your doctor will decide whether to continue treatment. Do not stop taking Losartán/Hidroclorotiazida Mabo on your own.
TakingLosartán/Hidroclorotiazida Mabowith food and drinks
It is recommended that you do not drink alcohol while taking these tablets: alcohol and Losartán/Hidroclorotiazida Mabo tablets may increase the effects of each other.
Excessive salt in the diet may counteract the effect of Losartán/Hidroclorotiazida Mabo tablets.
Losartán/Hidroclorotiazida Mabo tablets can be taken with or without food.
Pregnancy and breastfeeding
Pregnancy
You must inform your doctor if you are pregnant (or if you suspect that you may be). Your doctor will usually recommend that you stop taking Losartán/Hidroclorotiazida Mabo before becoming pregnant or as soon as you know you are pregnant and will recommend that you take another medicine instead of Losartán/Hidroclorotiazida Mabo. Losartán/Hidroclorotiazida Mabo is not recommended for use at the start of pregnancy, and in any case, it should not be administered from the third month of pregnancy onwards as it may cause serious harm to your baby when administered from that time onwards.
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. Losartán/Hidroclorotiazida Mabo is not recommended for use during breastfeeding, and your doctor will choose another treatment for you if you wish to breastfeed.
Consult your doctor or pharmacist before using any medicine.
Children and adolescents
There is no experience with the use of Losartán/Hidroclorotiazida in children. Therefore, Losartán/Hidroclorotiazida Mabo should not be administered to children.
Use in elderly patients
Losartán/Hidroclorotiazida Mabo acts with equal efficacy and is equally well tolerated by most elderly patients and young adults. Most elderly patients require the same dose as younger patients.
Driving and operating machines
When you start treatment with this medicine, you should not perform tasks that require special attention (e.g. driving a car or using hazardous machinery) until you know how you tolerate your medicine.
Use in athletes
This medicine contains hydrochlorothiazide, which may produce a positive result in doping control tests.
Losartán/Hidroclorotiazida Mabo contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Follow exactly the administration instructions for LOSARTÁN/HIDROCLOROTIAZIDA MABO as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again. Your doctor will decide the appropriate dose of LOSARTÁN/HIDROCLOROTIAZIDA MABO based on your condition and whether you are taking other medications. It is essential to continue taking LOSARTÁN/HIDROCLOROTIAZIDA MABO as prescribed by your doctor to maintain consistent blood pressure control.
Hypertension
For most patients with high blood pressure, the usual dose is 1 tablet of losartán/hidroclorotiazida 50 mg/12.5 mg per day to control blood pressure for 24 hours. It can be increased to 2 tablets of losartán/hidroclorotiazida 50 mg/12.5 mg per day or changed to 1 tablet of losartán/hidroclorotiazida 100 mg/25 mg (a higher dose) per day. The maximum daily dose is 2 tablets of 50 mg losartán/12.5 mg hidroclorotiazida per day or 1 tablet of 100 mg losartán/25 mg hidroclorotiazida per day.
If you take more LOSARTÁN/HIDROCLOROTIAZIDA MABO than you should
In case of an overdose, contact your doctor immediately or go directly to the hospital for immediate medical attention.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
An overdose may cause a drop in blood pressure, palpitations, slow pulse, changes in blood composition, and dehydration.
If you forgot to take LOSARTÁN/HIDROCLOROTIAZIDA MABO
Try to take LOSARTÁN/HIDROCLOROTIAZIDA MABO at the same time each day as prescribed. However, if you miss a dose, do not take an extra dose. Simply return to your regular schedule.
If you experience the following, stop taking the tablets ofLosartán/Hidroclorotiazida Maboand inform your doctor immediately or go to the emergency service of your nearest hospital:
Severe allergic reaction (skin rash, itching, swelling of the face, lips, mouth, or throat that may cause difficulty swallowing or breathing).
This is a serious but rare side effect that affects more than 1 in 10,000 patients but less than 1 in 1,000. You may need urgent medical attention or hospitalization.
The following side effects have been reported:
Frequent (may affect up to 1 in 10 people):
Less frequent (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people)
Frequency "unknown" (the frequency cannot be estimated from available data):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep out of the reach and sight of children.
Do not useLosartán/Hidroclorotiazida Maboafter the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
StoreLosartán/Hidroclorotiazida Maboin the original packaging.
Keep the blister in the outer packaging. Do not open the blister until ready to take the tablet.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging andthe medicines that you no longer need at the SIGREcollection point at the pharmacy. If in doubtask your pharmacist how to dispose of the packaging and the medicines that you no longer need. By doing so, you will help protect the environment.
Composition ofLosartán/Hidroclorotiazida Mabo
The active principles are losartan potassium and hydrochlorothiazide.
Each Losartán/Hidroclorotiazida Mabo tablet contains, as active principles, 50mg of losartan (potassium) and 12.5mg of hydrochlorothiazide.
Losartán/Hidroclorotiazida Mabo contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, pregelatinized cornstarch, magnesium stearate.
Losartán/Hidroclorotiazida Mabo 50mg/12.5mg contains 4.24 mg (0.108mEq) of potassium.
Losartán/Hidroclorotiazida Mabo also contains hydroxypropyl cellulose (hypromellose), hydroxypropyl methylcellulose (hypromellose), titanium dioxide (E-171), talc, iron oxide yellow (E-172).
Appearance of the product and content of the packaging
Losartán/Hidroclorotiazida Mabo is supplied as yellow-coated tablets with a score line on one face, elongated.
Losartán/Hidroclorotiazida Mabo is supplied in the following packaging sizes:
Aluminum/PVC/PE/PVDC blister packs containing 28 tablets.
Marketing Authorization Holder
MABO-FARMA S.A.
Calle Rejas 2, 1st floor28821
Coslada Madrid
Spain
Responsible for Manufacturing
Meiji Pharma Spain S.A.
Avda. de Madrid 94 Alcala de Henares (Madrid) - 28802 – Spain
Last revision date of this leaflet:February 2025
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.